The impact of device-assisted therapies on the gut microbiome in Parkinson's disease.

导出 LinkOut

翻译打印收藏纠错

作者： Michal,Lubomski ^[1] ; Xiangnan,Xu ^[2] ; Andrew J,Holmes ^[3] ; Jean Y H,Yang ^[4] ; Carolyn M,Sue ^[5] ; Ryan L,Davis ^[6]

作者单位： Department of Neurology, Clinical Admin 3E, Level 3, ASB, Royal North Shore Hospital, Northern Sydney Local Health District, Reserve Rd, St Leonards, NSW, 2065, Australia. mlub6241@uni.sydney.edu.au. ^[1] Department of Neurogenetics, Faculty of Medicine and Health, Kolling Institute, University of Sydney and Northern Sydney Local Health District, St Leonards, NSW, Australia. mlub6241@uni.sydney.edu.au. ^[2] School of Medicine, The University of Notre Dame Australia, Sydney, NSW, Australia. mlub6241@uni.sydney.edu.au. ^[3] School of Mathematics and Statistics, Sydney Precision Bioinformatics, University of Sydney, Camperdown, Sydney, NSW, Australia. ^[4] School of Life and Environmental Sciences, University of Sydney, Camperdown, Sydney, NSW, Australia. ^[5] The Charles Perkins Centre, University of Sydney, Camperdown, Sydney, NSW, Australia. ^[6] Department of Neurology, Clinical Admin 3E, Level 3, ASB, Royal North Shore Hospital, Northern Sydney Local Health District, Reserve Rd, St Leonards, NSW, 2065, Australia. ^[7] Department of Neurogenetics, Faculty of Medicine and Health, Kolling Institute, University of Sydney and Northern Sydney Local Health District, St Leonards, NSW, Australia. ^[8]

关键词 Deep brain stimulation (DBS)Device-assisted therapies Gastrointestinal microbiome Gut microbiota Levodopa–carbidopa intestinal gel (LCIG)Parkinson’s disease

主题词抗震颤麻痹药(Antiparkinson Agents);卡比多巴(Carbidopa);复方合剂(Drug Combinations);凝胶类(Gels);人类(Humans);左旋多巴(Levodopa);帕金森病(Parkinson Disease)

DOI 10.1007/s00415-021-10657-9

PMID 34128115

发布时间 2022-07-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交